Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
2022 · Cells · 26 citations
https://doi.org/10.3390/cells11244085
H
Hui Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
60
Papers
493
Citations
10
h-index
10
i10-index
Hui Wang is an academic researcher from Shandong Tumor Hospital. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Lymphocytic Leukemia Research & CAR-T cell therapy research. The author has an h-index of 10, co-authored 51 publications.
ORCID: 0000-0002-3470-4159Papers by this author
worksImmunological and clinicopathological characteristics of C1RL in 2120 glioma patients
2020 · BMC Cancer · 13 citations
https://doi.org/10.1186/s12885-020-07436-6
Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China
2025 · EClinicalMedicine · 0 citations
https://doi.org/10.1016/j.eclinm.2025.103688
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat